Lasse Lykke Nielsen

Effect of once‐weekly semaglutide versus thrice‐daily insulin aspart, both as add‐on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes ( <scp>SUSTAIN</scp> 11): A randomized, open‐label, multinational, phase 3b trial

Monika Kellerer, Margit S. Kaltoft, Jack Lawson et al. · Diabetes Obesity and Metabolism · 2022 · 66 citations · Full text

Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial

Aixin Shi, Panpan Xie, Lasse Lykke Nielsen et al. · Advances in Therapy · 2020 · 25 citations · Full text